Guo-Wei He

Prof. Dr. Guo-Wei He

TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
+1
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Guo-Wei HeGuo-Wei He
Guo-Wei He
DTDavid P. Taggart
David P. Taggart

22 November 2019 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
QYQin Yang
Qin Yang
Guo-Wei HeGuo-Wei He
Guo-Wei He
While the role of hyperhomocysteinemia in cardiovascular pathogenesis continuously draws attention, deficiency of hydrogen sulfide (H2S) has been growingly implicated in cardiovascular diseases. Generation of H2S is closely associated with the metabolism of homocysteine via key enzymes such as cystathionineβ-synthase (CBS) and cystathionineγ-lyase (CSE). The level of homocysteine and H2S is regulated by each other. Metabolic switch in the activity of CBS and CSE may occur with a resultant operating preference change of these enzymes in homocysteine and H2S metabolism. This paper presented an overview regarding (1) linkage between the metabolism of homocysteine and H2S, (2) mutual regulation of homocysteine and H2S, (3) imbalance of homocysteine and H2S in cardiovascular disorders, (4) mechanisms underlying the protective effect of H2S against homocysteine-induced vascular injury, and (5) the current status of homocysteine-lowering and H2S-based therapies for cardiovascular disease. The metabolic imbalance of homocysteine and H2S renders H2S/homocysteine ratio a potentially reliable biomarker for cardiovascular disease and development of drugs or interventions targeting the interplay between homocysteine and H2S to maintain the endogenous balance of these two molecules may hold an even bigger promise for management of vascular disorders than targeting homocysteine or H2S alone.

1 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAshenafi Betrie
Ashenafi Betrie
JBJames A. Brock
James A. Brock
OHOsama Harraz
Osama Harraz
Ashley I. BushAshley I. Bush
Ashley I. Bush
Guo-Wei HeGuo-Wei He
Guo-Wei He
SAScott Ayton
Scott Ayton
Zinc, an abundant transition metal, serves as a signalling molecule in several biological systems. Zinc transporters are genetically associated with cardiovascular diseases but the function of zinc in vascular tone regulation is unknown. We found that elevating cytoplasmic zinc using ionophores relaxed rat and human isolated blood vessels and caused hyperpolarization of smooth muscle membrane. Furthermore, zinc ionophores lowered blood pressure in anaesthetized rats and increased blood flow without affecting heart rate. Conversely, intracellular zinc chelation induced contraction of selected vessels from rats and humans and depolarized vascular smooth muscle membrane potential. We demonstrate three mechanisms for zinc-induced vasorelaxation: (1) activation of transient receptor potential ankyrin 1 to increase calcitonin gene-related peptide signalling from perivascular sensory nerves; (2) enhancement of cyclooxygenase-sensitive vasodilatory prostanoid signalling in the endothelium; and (3) inhibition of voltage-gated calcium channels in the smooth muscle. These data introduce zinc as a new target for vascular therapeutics.

14 April 2011 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
JHJunhao Huang
Junhao Huang
Guo-Wei HeGuo-Wei He
Guo-Wei He
HXHong-Mei Xue
Hong-Mei Xue
Xiaoqiang YaoXiaoqiang Yao
Xiaoqiang Yao
XLXiao-Cheng Liu
Xiao-Cheng Liu
QYQin Yang
Qin Yang
Intracellular Ca2+ ([Ca2+]i) regulation in endothelial cells depends on transient receptor potential channels (TRPs), and the role of canonical TRPs (TRPCs) during hypoxia–reoxygenation (H–R) is unclear. We hypothesized that TRPC3 contributes to endothelial nitric oxide (NO) release and that H–R may reduce TRPC3 activity and the associated endothelial function, including NO release. Measurements of [Ca2+]i and patch-clamp study in primary cultured porcine coronary endothelial cells, measurements of NO and endothelium-dependent relaxation in porcine coronary arteries, and RT-PCR and western blot were conducted. Pre-treatment with SKF96365 (an inhibitor of TRPCs) or the selective TRPC3 inhibitor Pyr3 significantly decreased bradykinin-induced vasorelaxation. One hour of hypoxia followed by reoxygenation significantly reduced the vasorelaxation (70.3 ± 6.4 vs. 88.9 ± 3.5%) and NO concentration (24.0 ± 1.3 vs. 45.2 ± 2.8 nmol/L), and they were restored by pre-incubation with the TRPC3/6/7 activator 1-oleoyl-2-acetyl-sn-glycerol (96.4 ± 1.8% and 41.1 ± 4.7 nmol/L, respectively). In porcine coronary endothelial cells, H–R inhibited bradykinin-activated membrane current (8.6 ± 0.4 vs. 14.0 ± 1.5 pA/pF) and Pyr3-sensitive TRPC3 current (3.8 ± 0.3 vs. 6.3 ± 0.6 pA/pF; P< 0.01). H–R also inhibited bradykinin-induced Ca2+ influx and the Ca2+ influx via TRPC3. Cell surface expression of TRPC3 was decreased after H–R. We have, for the first time, demonstrated that Ca2+ entry via endothelial TRPC3 contributes to NO release and have revealed that H–R is associated with inhibition of TRPC3 activity. Inhibition of channel trafficking to the cell surface is involved in the underlying mechanism of the decrease of TRPC3 current and the reduction in Ca2+ entry through TRPC3 during H–R. This study suggests that TRPC3 may have the potential to be a new target for endothelial protection during H–R.

4 December 2014 in Scientific Reports
Verified
Journal Article
Open access
CXChao Xuan
Chao Xuan
HLHui Li
Hui Li
JZJin-Xia Zhao
Jin-Xia Zhao
HWHong-Wei Wang
Hong-Wei Wang
YWYi Wang
Yi Wang
LLLi-Min Lun
Li-Min Lun
The aim of our study was to evaluate the association between polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene and the risk for congenital heart disease (CHD). Electronic literature databases were searched to identify eligible studies published before Jun, 2014. The association was assessed by the odds ratio (OR) with a 95% confidence interval (CI). The publication bias was explored using Begg's test. Sensitivity analysis was performed to evaluate the stability of the crude results. A total of 35 studies were included in this meta-analysis. For the MTHFR C677T polymorphism, we detected significant association in all genetic models for Asian children and the maternal population. Significant association was also detected in T vs. C for a Caucasian paediatric population (OR = 1.163, 95% CI: 1.008–1.342) and in both T vs. C (OR = 1.125, 95% CI: 1.043–1.214) and the dominant model (OR = 1.216, 95% CI:b1.096–1.348) for a Caucasian maternal population. For the MTHFR A1298C polymorphism, the association was detected in CC vs. AC for the Caucasian paediatric population (OR = 1.484, 95% CI: 1.035–2.128). Our results support the MTHFR -677T allele as a susceptibility factor for CHD in the Asian maternal population and the -1298C allele as a risk factor in the Caucasian paediatric population.

8 March 2011 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
QYQin Yang
Qin Yang
HXHong‐Mei Xue
Hong‐Mei Xue
Wing Tak WongWing Tak Wong
Wing Tak Wong
XTXiao Yu Tian
Xiao Yu Tian
Yu HuangYu Huang
Yu Huang
Guo-Wei HeGuo-Wei He
Guo-Wei He
BACKGROUND AND PURPOSE Nitric oxide (NO) plays an important role in endothelial function, and impaired NO production is involved in hypertension. Therefore, compounds that regulate endothelial NO synthase (eNOS) may be of therapeutic benefit. A novel, low molecular weight compound AVE3085 is a recently developed compound with the ability to enhance eNOS transcription. The present study investigated the effects of AVE3085 in endothelial dysfunction associated with hypertension.EXPERIMENTAL APPROACH Spontaneously hypertensive rats (SHRs) were treated with AVE 3085 (10 mg·kg·day−1, orally) for 4 weeks. Isometric force measurement was performed on rings of isolated aortae in organ baths. Protein expression of eNOS, phosphorylated‐eNOS and nitrotyrosine in the aortae were examined by Western blotting. mRNA for eNOS in rat aortae were examined by reverse‐transcriptase polymerase chain reaction (RT‐PCR).KEY RESULTS AVE3085 greatly improved endothelium‐dependent relaxations in the aortae of SHRs. This functional change was accompanied by up‐regulated expression of eNOS protein and mRNA, enhanced eNOS phosphorylation and decreased formation of nitrotyrosine. Furthermore, AVE3085 treatment reduced the blood pressure in SHR without affecting that of hypertensive eNOS−/− mice.CONCLUSIONS AND IMPLICATIONS The eNOS‐transcription enhancer AVE3085 restored impaired endothelial function in a hypertensive model. The present study provides a solid basis for the potential development of eNOS‐targeting drugs to restore down‐regulated eNOS, as a new strategy in hypertension.